NCT05778149 2023-03-21Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationTianjin Medical University Cancer Institute and HospitalPhase 2 Not yet recruiting47 enrolled